NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP
Avanos Medical, Inc. AVNS
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$701.2M
▲ 1.9% vs FY2024
EPS · FY25
$-1.57
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-9.1%
Net margin · FY25
-10.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 701.2M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
USD -1.57
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-9.1%
Return on equity, FY2025
ROE
Operating margin-8.8%
Net margin-10.4%
Return on assets-6.5%
Each USD of equity lost 9 cents this year.
Returned to shareholders
USD 2.6M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 2.6M
Share of profit-3.6%
Consecutive raises—
USD 2.6M in buybacks went back to shareholders in a year without profit.
Growth
−0.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.8%
−0.4%
+3.3%
Returned to shareholders
−61.0%
+23.6%
+10.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years−3.0%
Change, 10 years−0.3%
The share count shrank 3% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 778.2M
CashUSD 89.8M
Gross debtUSD 100.5M
Net debtUSD 10.7M
Current ratio2.15×
Net debt stands at 1% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.7
0.7
0.7
0.7
0.6
0.7
0.7
0.7
0.6
0.6
0.5
1.7
1.7
1.7
Operating income $B
−0.1
−0.4
0.0
0.0
−0.0
−0.0
−0.1
0.0
−0.0
−0.1
−0.1
0.1
0.2
0.2
EBITDA $B
−0.0
−0.4
0.1
0.1
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.1
0.2
0.3
0.3
Income tax $B
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
0.1
0.1
0.1
Net income $B
−0.1
−0.4
−0.1
0.1
0.0
−0.0
−0.0
0.1
0.1
0.0
−0.4
0.0
0.2
0.2
EPS, diluted $
−1.57
−8.53
−1.32
1.07
0.13
−0.61
−0.96
1.22
1.69
0.85
−9.15
0.58
3.32
3.28
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
0
·
·
·
·
·
·
ROE %
−9.1
−38.0
−4.9
3.9
0.5
−2.3
−3.6
4.6
6.8
3.7
−33.5
1.5
7.5
7.4
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
53 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed